Lineage Cell Therapeutics (LCTX) announced the receipt of an induced pluripotent stem cell line containing hypoimmunity edits, from Factor ...
Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...
1d
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, ...
DALLAS--(BUSINESS WIRE)--Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced ...
A novel iPSC-derived lung-on-chip model mimics human alveolar tissue, revealing macrophage-driven tuberculosis responses.
Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma Patient-specific human immune system-bearing mouse ...
Lung-on-chip model made of cells derived from a single person furthers understanding of tuberculosis and potential ...
Cells can be reprogrammed, edited and differentiated into a wide variety of iPSC-derived cell types and 3-dimensional human cell models. iPSCore ™ incorporates extensive characterization, ...
This image shows how human iPSCs in which the microglia-specifying six-TF cocktail is switched on (lower row), in contrast to iPSCs in which they remain switched off (upper row), abandon their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback